Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study to evaluate the safety, pharmacokinetics(PK), and preliminary
clinical activity of KPG-818 as a single agent in adult subjects with selected hematological
malignancies, including multiple myeloma (MM), mantle cell lymphoma (MCL), follicular
lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), indolent lymphoma, adult T-cell
leukemia-lymphoma (ATL), or chronic lymphocytic leukemia (CLL). This study will assist in
identifying appropriate, well tolerated doses that can be administered in subsequent studies
in subjects with selected hematological malignancies.